Bispecific antibodies (BsAbs) are synthetic proteins that can target two discrete epitopes from different antigens. Originally developed for cancer therapeutics, scientists now explore BsAb applications for the prevention and treatment of other diseases, as well as imaging and diagnostics. Several bispecific antibodies have already obtained regulatory approval, while hundreds more are in development.
Download this white paper from Curia to learn more about BsAbs, their predominant formats, their mechanisms of action, the most common techniques for their production, and how partnering with a contract development and manufacturing organization (CDMO) can deliver precise immunotherapy solutions while avoiding costly regulatory mistakes.
